Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Large B-Cell, Diffuse 12Lymphoma, B-Cell 10Recurrence 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Multiple Myeloma 5Lymphoma, Mantle-Cell 5Burkitt Lymphoma 5Lymphoma, Follicular 4Lymphoma 4Neoplasms 3Neoplasm, Residual 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, B-Cell, Marginal Zone 2Breast Neoplasms 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Pyloric Stenosis, Hypertrophic 1Platinum-Resistant Ovarian Carcinoma 1Plasmacytoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Nasopharyngeal Carcinoma 1Mesothelioma, Malignant 1Meningeal Carcinomatosis 1

Interventions

Dexamethasone 3daratumumab 2Lenalidomide 2pomalidomide 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1dexamethasone acetate 1dexamethasone 21-phosphate 1cc-486 1carfilzomib 1auricularum 1Specimen Handling 1Radiotherapy 1Immunotherapy, Adoptive 1Calcium Dobesilate 1Bortezomib 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Plasmacytoma × Immunotherapy, Adoptive × 1 year × Clear all
NCT06429150 2026-04-24

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Shenzhen Geno-Immune Medical Institute

Phase 1/2 Recruiting
20 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡